RGRoxanne Gal

Roxanne Gal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roxanne Gal has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Anne M. May

    Julius Center for Health Sciences and Primary care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

    5 shared publications
  • Evelyn M. Monninkhof

    Julius Center for Health Sciences and Primary care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

    5 shared publications
  • Helena M. Verkooijen

    Affiliations Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands, Imaging Cluster, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands

    5 shared publications
  • Anne M. May

    Julius Center for Health Sciences and Primary care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

    3 shared publications
  • Helena M. Verkooijen

    Division of Imaging and Oncology, University Medical Centre Utrecht, Utrecht, The Netherlands

    3 shared publications
  • Jorrit-Jan Verlaan

    Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

    3 shared publications

Latest Publications

  • Open Access

    Effect of yoga on musculoskeletal complaints in women during endocrine treatment for breast cancer: protocol of the randomised controlled COBRA trial

    by Stefanie G A Veenhuizen, Roxanne Gal, Holger Cramer, Rhodé M Bijlsma, Patricia Blickle, Job van der Palen, Quinty R C M Wagenaar, Esther van Leer, Inge Konings, Desirée H J G van Den Bongard, et al.

    Introduction Approximately 40% of women stop endocrine therapy for hormone-receptor-positive breast cancer within the first 5 years of prescribed treatment because of side effects. Musculoskeletal complaints are among the most frequently reported side effects. The Cancer Of the BReast Asanas (COBRA) study examines the effect of an 18-week yoga programme on endocrine therapy-associated musculoskeletal complaints in women with breast cancer. Methods and analysis In total, 140 women will be randomised in a 1:1 ratio to the intervention or waitlist control group. The intervention programme consists of two times a week 1-hour supervised Hatha or (easy) Vinyasa yoga classes at a yoga or sports centre for 18 weeks and once per week a half-hour at home using videos. The waitlist control group is asked to maintain their habitual lifestyle during the first 18 weeks and will participate in a similar yoga programme to the intervention group for the following 18 weeks. The control group yoga programme is offered live-remote. The primary outcome (musculoskeletal complaints) is assessed with the Brief Pain Inventory questionnaire at baseline and 18 weeks (primary comparison) and additionally at 36 weeks. Secondary outcomes include lower and upper extremity joint complaints, menopausal symptoms, fatigue, sleep, quality of life, anxiety and depression, cognitive complaints and habitual physical activity (all patient-reported), vital signs and anthropometrics, physical fitness, blood biomarkers, medication use, safety data and patient and teacher experiences. At baseline and 18 weeks, cognitive complaints are also assessed with an online neuropsychological test battery. Ethics and dissemination The COBRA study was approved by the Medical Ethical Committee of the University Medical Center Utrecht. The study started on 8 October 2024, and 65 participants have been included (20 January 2026). Results will be submitted to an international peer-reviewed journal. Trial registration number NCT06480513.

  • Open Access

    Timely Integration of specialist palliative care into oncology care for patients receiving radiotherapy for bone metastases: A study procotol for the TIPZO-RT Randomized Controlled Trial

    by Anouk van Oss, Joanne M. van der Velden, Helena M. Verkooijen, Rebecca van Jaarsveld, Ginette M. Hesselmann, Evelien J.M. Kuip, Paulien G. Westhoff, Natasja J.H. Raijmakers, Yvette M. van der Linden, Roxanne Gal

    Background: Patients living with advanced cancer often benefit from palliative care. Timely referral to specialist palliative care improves quality of life and reduces potentially inappropriate end-of-life care. Despite these benefits, specialist palliative care is frequently introduced late and inconsistently. This study evaluates whether systematically offering a consultation with the hospital palliative care consultation team (PCCT) to all patients referred for radiotherapy for symptomatic bone metastases improves satisfaction with care. Patients and Methods: The Timely Integration of Palliative Care in Oncology care for patients referred for palliative RadioTherapy (TIPZO-RT) trial follows the Trials within Cohorts design and is embedded within the PRospective Evaluation of interventional StudiEs on boNe meTastases (PRESENT+) cohort. Following cohort enrollment, 246 patients will be randomized (1:1) to either the intervention or control group. Patients in the intervention group are offered a PCCT consultation, which they may accept or refrain from. Patients in the control group are not informed about the trial and continue to receive usual care. After four weeks, patient satisfaction with care (affective behavior, EORTC Satisfaction with Cancer Care core questionnaire (EORTC PATSAT-C33)) will be compared between the groups. Secondary outcomes include symptom burden, quality of life, overall survival, and palliative care utilization. Additionally, in the intervention group, patients’ experiences with the consultation are evaluated. Discussion: Integrating palliative care into oncological care for patients with advanced cancer is essential to deliver comprehensive, patient-centered care that addresses physical, psychosocial and spiritual needs. This pragmatic study may provide evidence to support timely integration of specialist palliative care for all patients with bone metastases who may benefit from specialist palliative care. Using the Trials within Cohorts design, this study generates real-world evidence on the acceptance or need for a consultation with the PCCT, while minimizing disappointment or response bias, as patients in the control group are not informed. Trial registration: ClinicalTrials.gov ID NCT06805396 . Registered on 25-03-2025.

  • Open Access

    Course of quality of life in short- and long-term survivors after radiotherapy for bone metastases

    by Eline H. Huele, Renée Hovenier, Bas B.J. Bindels, Anouk van Oss, Rene H. Kuijten, Roxanne Gal, Bart J. Pielkenrood, Jorrit-Jan Verlaan, Nicolien Kasperts, Wietse S.C. Eppinga, et al.

  • Open Access

    Tailored guidance to apply the Estimand framework to Trials within Cohorts (TwiCs) studies

    by R. Gal, R. Kessels, K. Luijken, L.A. Daamen, D.R. Mink van der Molen, S.A.M. Gernaat, A.M. May, H.M. Verkooijen, P.M. van de Ven


  • Open Access

    Stereotactic Body radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases: a randomized trial (BLEND RCT) using the Trials within Cohorts (TwiCs) design

    by E. H. Huele, J. M. van der Velden, N. Kasperts, W. S. C. Eppinga, J. P. C. Grutters, B. B. M. Suelmann, A. A. Weening, D. Delawi, S. C. C. M. Teunissen, H. M. Verkooijen, et al.

    Background: Spinal metastases can lead to unremitting pain and neurological deficits, which substantially impair daily functioning and quality of life. Patients with unstable spinal metastases receive surgical stabilization followed by palliative radiotherapy as soon as wound healing allows. The time between surgery and radiotherapy delays improvement of mobility, radiotherapy-induced pain relief, local tumor control, and restart of systemic oncological therapy. Stereotactic body radiotherapy (SBRT) enables delivery of preoperative high-dose radiotherapy while dose-sparing the surgical field, allowing stabilizing surgery within only hours. Patients may experience earlier recovery of mobility, regression of pain, and return to systemic oncological therapy. The BLEND RCT evaluates the effectiveness of SBRT followed by surgery within 24 h for the treatment of symptomatic, unstable spinal metastases. Methods: This phase III randomized controlled trial is embedded within the PRospective Evaluation of interventional StudiEs on boNe meTastases (PRESENT) cohort. Patients with symptomatic, unstable spinal metastases requiring stabilizing surgery and radiotherapy will be randomized (1:1). The intervention group (n = 50) will be offered same-day SBRT and surgery, which they can accept or refuse. According to the Trial within Cohorts (TwiCs) design, the control group (n = 50) will not be informed and receive standard treatment (surgery followed by conventional radiotherapy after 1–2 weeks when wound healing allows). Baseline characteristics and outcome measures will be captured within PRESENT. The primary outcome is physical functioning (EORTC-QLQ-C15-PAL) 4 weeks after start of treatment. Secondary endpoints include pain response, time until return to systemic oncological therapy, quality of life, local tumor control, and adverse events up to 3 months post-treatment. Discussion: The BLEND RCT evaluates the effect of same-day SBRT and stabilizing surgery for the treatment of symptomatic, unstable spinal metastases compared with standard of care. We expect better functional outcomes, faster pain relief, and continuation of systemic oncological therapy. The TwiCs design enables efficient recruitment within an ongoing cohort, as well as prevention of disappointment bias and drop-out as control patients will not be informed about the trial. Trial registration: ClinicalTrials.gov NCT05575323. Registered on October 11, 2022.


  • Open Access

    Translating Evidence from Dutch Exercise Oncology Trials in Patients with Breast Cancer into Clinical Practice Using the RE‐AIM Framework

    by Marieke R. Ten Tusscher, Martijn M. Stuiver, Caroline S. Kampshoff, Rosalie J. Huijsmans, Neil K. Aaronson, Miranda Velthuis, Roxanne Gal, Hanna Van Waart, Anne M. May, Laurien M. Buffart

    Purpose . We aimed to evaluate the potential for implementing exercise interventions for patients with breast cancer in the Netherlands, based on findings of the Dutch randomized controlled trials in this population. Methods . We evaluated the implementation of four Dutch exercise trials retrospectively, using the five dimensions of the RE‐AIM framework: Reach (exercise participation rate), Effectiveness for physical fitness, fatigue, quality of life, and physical function, Adoption (e.g., satisfaction of physical therapists guiding the exercise intervention), Implementation (cost‐effectiveness and exercise adherence correlates thereof), and Maintenance (maintenance of exercise levels by individual patients and sustainability of exercise delivery at organization level). Thereby, we reflect on these results using (international) literature to gain better insight in overall barriers, facilitators, and opportunities for further implementation of exercise interventions. Results . Participation rates of 44–52% not only indicated acceptable Reach in the context of a trial but also indicated room for improvement. Effectiveness of exercise during and after treatment was demonstrated in most trials showing benefits for aerobic fitness, physical fatigue, quality of life and physical function, and high patient satisfaction. Adoption of the exercise interventions by physical therapists was adequate (satisfaction score: 7.5 out of 10). Evaluation of Implementation indicated adequate adherence to supervised exercise, inconsistent findings on potential correlates of adherence, and promising results on cost‐effectiveness. Currently, reimbursement for exercise programs is lacking. Maintenance of intervention effects at the patient level was limited and inconsistent. Maintenance of intervention availability at the organizational level was facilitated by an extensive network of specially trained physical therapists, but better communication and collaboration between different healthcare professionals are desired. Conclusions . Improved implementation could particularly be achieved by increasing reach and improved focus on exercise maintenance on both the patient and organizational level.


  • Open Access

    Translation and validation of the Dutch Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ2.0) to evaluate health-related quality of life in patients with symptomatic spinal metastases

    by Roxanne Gal, Joanne M van der Velden, Daimy C Bach, Jorrit-Jan Verlaan, Ruth E Geuze, Joost Phj Rutges, Helena M Verkooijen, Anne L Versteeg

    Background: The primary goal of palliative treatment of spinal metastases is to maintain or improve health-related quality of life (HRQOL). We translated and validated a Dutch version of The Spine Oncology Study Group Outcome Questionnaire (SOSGOQ2.0), a valid and reliable 20-item questionnaire to evaluate HRQOL in patients with spinal metastases. Methods: After cross-cultural translation and adaptation, the questionnaire was pre-tested in fifteen patients referred for spine surgery and/or radiotherapy. This resulted in a final questionnaire that was sent to patients for assessment of internal consistency, construct (i.e., convergent and divergent) validity, discriminative power and test-retest reliability. Results: Overall, 147 patients (mean age 65.6 years, SD = 10.4) completed the questionnaire after a median time of 45.4 months (IQR = 18.9–72.9) after spine surgery and/or radiotherapy. Internal consistency was good for the Physical function, Pain, and Mental health domains (α = 0.87, 0.86, 0.72), but not for Social function (α = 0.04). Good convergent validity was demonstrated except for Social function (rs = 0.37 95%CI = 0.21–0.51). Discriminative power between patients with ECOG performance scores of 0–1 and 2–4 was found on all domains and Neurological function items. Test-retest reliability was acceptable for Physical function, Pain and Mental health (ICC = 0.89 95%CI = 0.81–0.94, ICC = 0.88 95%CI = 0.78–0.93, ICC = 0.68 95%CI = 0.48–0.81), whereas ICC = 0.45 (95%CI = 0.17–0.66) for Social function was below threshold. After removing item 20 from the Social function domain, internal consistency improved, and convergent validity and test-retest reliability were good. Conclusion: The Dutch version of the SOSGOQ2.0 questionnaire is a reliable and valid tool to measure HRQOL in patients with spinal metastases. Item 20 was removed to retain psychometric properties.


  • Open Access

    Patient Expectations About Palliative Treatment for Symptomatic Spinal Metastases: A Qualitative Study

    by Roxanne Gal, Raphäele Charest-Morin, Jorrit-Jan Verlaan, Charles G. Fisher, Hester Wessels, Helena M. Verkooijen, Anne L. Versteeg


  • Open Access

    Large Majority of Patients Report Positively or Neutrally of Unknowingly Having Served as Controls in the Trials within Cohorts (TwiCs) Design

    by Maaike Verweij, Roxanne Gal, Maarten Burbach, Danny Young-Afat, Joanne van der Velden, Rieke van der Graaf, Anne May, Clare Relton, Martijn Intven, Helena Verkooijen

    Objective: To evaluate patients’ experience of having served as controls without explicit notification in the context of the Trial within Cohorts (TwiCs) design. Study design: Cohort participants with breast or rectal cancer, who had served as controls in an exercise respectively radiotherapy dose-escalation TwiCs, were asked for their experience of having (unknowingly) served as controls in TwiCs in a survey. At cohort entry, patients had provided broad consent to randomization. Results: Survey response rates were 76% (n=110/145). Two to six years after cohort entry, 15% (n=16) of all patients remembered having provided broad consent to randomization. After disclosure of trial results, 53% (n=57) of patients thought positively, 41% (n=44) neutrally and 1% (n=1) negatively of having served as controls in one of the two trials. Twenty-two percent (n=24) of patients were positive, 62% (n=66) neutral and 7% (n=7) negative about not having been notified when serving as controls. Conclusions: A large majority of patients reported positively or neutrally of unknowingly having served as controls in TwiCs. The recollection of having provided broad consent to randomization was poor at 2-6 years after cohort entry.

  • Open Access

    Coronary artery calcifications on breast cancer radiotherapy planning CT scans and cardiovascular risk: What do patients want to know?

    by Roxanne Gal, Madelijn L. Gregorowitsch, Marleen J. Emaus, Erwin La. Blezer, Femke van der Leij, Sanne Gm. van Velzen, Julia J. van Tol-Geerdink, Ivana Išgum, Helena M. Verkooijen